Deborah Morosini
Net Worth

Last updated:

What is Deborah Morosini net worth?

The estimated net worth of Dr. Deborah Morosini is at least $2,480,444 as of 15 Dec 2021. He owns shares worth $378 as insider, has earned $846,016 from insider trading and has received compensation worth at least $1,634,050 in Prelude Therapeutics Incorporated.

What is the salary of Deborah Morosini?

Dr. Deborah Morosini salary is $326,810 per year as Executive Vice President & Chief of Clinical Affairs in Prelude Therapeutics Incorporated.

How old is Deborah Morosini?

Dr. Deborah Morosini is 66 years old, born in 1959.

What stocks does Deborah Morosini currently own?

As insider, Dr. Deborah Morosini owns shares in one company:

Company Title Shares Price per share Total value
Prelude Therapeutics Incorporated (PRLD) Executive Vice President & Chief of Clinical Affairs 444 $0.85 $378

What does Prelude Therapeutics Incorporated do?

Prelude Therapeutics Incorporated, a clinical-stage precision oncology company, focuses on the discovery and development of novel precision cancer medicines to underserved patients. It is developing PRT543 that is in Phase 1 clinical trials in select solid tumors and myeloid malignancies; and PRT811, which is in Phase 1 clinical trials in solid tumors, including glioblastoma multiforme. The company is also developing PRT1419, a potent and selective inhibitor of the anti-apoptotic protein; PRT2527, a potent inhibitor of CDK9 that exhibits high kinome selectivity; PRT-SCA2, which is in preclinical stage for multiple genomically selected cancers; PRT3645, a brain penetrant molecule that potently and selectively targets CDK4/6; and PRT-K4 that is in preclinical stage for solid tumors. The company was incorporated in 2016 and is headquartered in Wilmington, Delaware.

PRLD logo
PRLD
Prelude Therapeutics Incorporated
$0.85

Deborah Morosini insider trading

Prelude Therapeutics Incorporated

Dr. Deborah Morosini has made 5 insider trades between 2020-2021, according to the Form 4 filled with the SEC.

The largest trade he's ever made was exercising 28,751 units of PRLD stock on 16 Nov 2021. As of 15 Dec 2021 he still owns at least 444 units of PRLD stock.

Transaction Date Security Shares Price per share Total value Source
Option
Common Stock 25,735 $12.85 $330,695
Option
Employee Stock Option (right to buy) 3,016 $1.89 $5,700
Sale
Common Stock 28,751 $13 $373,763
Option
Common Stock 3,016 $1.89 $5,700
Option
Employee Stock Option (right to buy) 882 $12.85 $11,334
Option
Employee Stock Option (right to buy) 24,853 $12.85 $319,361
Sale
Common Stock 28,751 $16.15 $464,271
Option
Common Stock 28,751 $12.85 $369,450
Option
Employee Stock Option (right to buy) 28,751 $12.85 $369,450
Sale
Common Stock 3,223 $1.89 $6,091
Option
Common Stock 3,223 $1.89 $6,091
Option
Employee Stock Option (right to buy) 3,223 $1.89 $6,091
Sale
Common Stock 100 N/A N/A
Option
Common Stock 100 N/A N/A
Option
Employee Stock Option (right to buy) 100 N/A N/A
Option
Common Stock 1,000 $1.89 $1,890
Sale
Common Stock 1,000 $1.89 $1,890
Option
Employee Stock Option (right to buy) 1,000 $1.89 $1,890
Purchase
Common Stock 444 N/A N/A

Prelude Therapeutics Incorporated key executives

Prelude Therapeutics Incorporated executives and other stock owners filed with the SEC:

  • Dr. Deborah Morosini (66) Executive Vice President & Chief of Clinical Affairs
  • Dr. Krishna Vaddi D.V.M., Ph.D. (59) Founder, Chief Executive Officer & Director